                </a></li></ul></div><p><strong>Figure 2.  <span>Schematic diagram of the protocol for NDEPT.</span></strong></p><a id="article1.body1.sec2.sec9.fig2.caption1.p1" name="article1.body1.sec2.sec9.fig2.caption1.p1"></a><p>Human neuroblastoma tumor cells are injected intravenously to produce disseminated tumors.</p>
<a id="article1.body1.sec2.sec9.fig2.caption1.p2" name="article1.body1.sec2.sec9.fig2.caption1.p2"></a><p>At an appropriate time after injection of neuroblastoma cells, neural stem cells or neural progenitor cells transduced with adenovirus to express a prodrug-activating enzyme (in this study, a secreted form of rabbit carboxylesterase [rCE]) are injected intravenously.</p>
<a id="article1.body1.sec2.sec9.fig2.caption1.p3" name="article1.body1.sec2.sec9.fig2.caption1.p3"></a><p>Following migration of stem cells or progenitor cells to tumor foci and a delay of 3â€“4 days to allow relatively high level expression of the prodrug-activating enzyme into the extracellular milieu at the tumor sites, mice are treated with the prodrug (in this study, CPT-11).</p>
<a id="article1.body1.sec2.sec9.fig2.caption1.p4" name="article1.body1.sec2.sec9.fig2.caption1.p4"></a><p>The prodrug is activated selectively at tumor foci, to increase the therapeutic index of the prodrug.</p>
<span>THISISTHEEND
